Overview

Long Term Extension Study in Patients With Primary Hyperoxaluria

Status:
Enrolling by invitation
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The proposed study is designed to provide patients previously enrolled in Phase 1 and 2 studies of DCR-PHXC and their siblings (<18 years old) long-term access to DCR-PHXC, and to evaluate the long-term safety and efficacy of DCR-PHXC in patients with PH.
Phase:
Phase 3
Details
Lead Sponsor:
Dicerna Pharmaceuticals, Inc.